(Q38534943)

3 September 2017

1 reference

title

Prospects for a globally effective HIV-1 vaccine (English)

1 reference

3 September 2017

1

Jean-Louis Excler

1 reference

3 September 2017

2

Merlin L Robb

1 reference

3 September 2017

3

Jerome H Kim

1 reference

3 September 2017

language of work or name

English

0 references

publication date

19 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

33 Suppl 4

1 reference

3 September 2017

page(s)

D4-12

1 reference

HIV epidemic in Asia: optimizing and expanding vaccine development

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Behavior change interventions to prevent HIV infection among women living in low and middle income countries: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Progress, challenges, and new opportunities for the prevention of mother-to-child transmission of HIV under the US President's Emergency Plan for AIDS Relief

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

ARV-based HIV prevention for women - where we are in 2014.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Promising prevention approaches: tenofovir gel and prophylactic use of antiretroviral medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Preexposure prophylaxis for HIV infection among African women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Ending AIDS--is an HIV vaccine necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Global epidemiology of HIV infection in men who have sex with men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Worldwide burden of HIV in transgender women: a systematic review and meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Global trends in molecular epidemiology of HIV-1 during 2000-2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Implications of HIV diversity for the HIV-1 pandemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV-1 vaccines: challenges and new perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Novel directions in HIV-1 vaccines revealed from clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Moving ahead an HIV vaccine: use both arms to beat HIV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV vaccine efficacy and immune correlates of risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

A critical question for HIV vaccine development: which antibodies to induce?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV/AIDS: Allied responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Which Antibody Functions are Important for an HIV Vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Nomenclature for immune correlates of protection after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Predictive markers of safety and immunogenicity of adjuvanted vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

The mechanism of action of MF59 - an innately attractive adjuvant formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Selection of potent immunological adjuvants for vaccine construction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

7 January 2021

Nanoparticle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Germinal center B and follicular helper T cells: siblings, cousins or just good friends?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV-1 neutralizing antibodies: understanding nature's pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Lessons from babies: inducing HIV-1 broadly neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Early development of broadly neutralizing antibodies in HIV-1-infected infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Designing tomorrow's vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

A Blueprint for HIV Vaccine Discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Broad neutralization coverage of HIV by multiple highly potent antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Neutralizing antibodies to HIV-1 induced by immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Neutralizing antibody responses in macaques induced by human immunodeficiency virus type 1 monovalent or trivalent envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Adeno-associated virus delivery of broadly neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Antibody-based protection against HIV infection by vectored immunoprophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Challenges in the design of a T cell vaccine in the context of HIV-1 diversity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

CD8(+) T cells in preventing HIV infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Lessons learned from HIV-1 vaccine trials: new priorities and directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Development of replication-competent viral vectors for HIV vaccine delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 va

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Design and pre-clinical evaluation of a universal HIV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV-1 group M conserved elements vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Conserved HIV-1 epitopes continuously elicit subdominant cytotoxic T-lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Optimizing parallel induction of HIV type 1-specific antibody and T-cell responses by multicomponent subunit vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Immune clearance of highly pathogenic SIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

Accelerating HIV-1 Vaccine Efficacy Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.03.059

10.1016/J.VACCINE.2015.03.059

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference